Related Experiment Videos
[Ischemic encephalopathy in primary antiphospholipid syndrome]
P Thomas1, C Lebrun, M H Mahagne
1Service de Neurologie, Hôpital Pasteur, Nice.
Revue Neurologique
|January 1, 1993
Summary
Sneddon's syndrome, a condition involving antiphospholipid antibodies, showed no improvement with standard treatments like anticoagulation and plasma exchange. This case highlights the need for better therapies for antiphospholipid antibody-associated stroke.
Area of Science:
- Neurology
- Immunology
- Vascular Medicine
Background:
- Antiphospholipid antibody syndrome (APS) is an autoimmune disorder associated with an increased risk of thrombosis.
- Sneddon's syndrome is a rare, non-inflammatory occlusive hydrocephalus characterized by livedo reticularis and neurological deficits, often linked to APS.
- Current treatment strategies for APS-related neurological events primarily involve anticoagulation and immunosuppressive therapies.
Observation:
- A 39-year-old male patient presented with livedo reticularis, optic neuropathy, and acute ischemic encephalopathy, consistent with Sneddon's syndrome.
- The patient had persistently high antiphospholipid antibody titers.
- Neurological symptoms showed no improvement despite anticoagulation, corticosteroid therapy, and multiple plasma exchange sessions.
Findings:
- Plasma exchange led to a significant reduction in circulating antiphospholipid antibody titers.
- Despite the reduction in antibody levels, neurological symptoms remained refractory to treatment.
- The patient ultimately succumbed to a systemic complication of the disease, even when antibody titers were at their lowest.
Implications:
- This case underscores the limitations of current therapeutic approaches for Sneddon's syndrome and APS-related ischemic stroke.
- Effective treatment strategies for neurological manifestations of APS remain a significant unmet clinical need.
- Further research into novel therapeutic targets and treatment modalities for APS-associated cerebrovascular disease is warranted.